Patient considerations in the treatment of COPD: Focus on the new combination inhaler umeclidinium/vilanterol

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing. Once-daily dosing has been shown to be an important variable in medication adherence in chronic diseases, such as COPD. New inhalers that only require once-daily dosing are becoming more widely available. Combination once-daily inhalers that combine any two of the following three agents are now available: 1) a long-acting muscarinic antagonist; 2) a long acting beta2 agonist; and 3) an inhaled corticosteroid. A new once-daily inhaler with both a long-acting muscarinic antagonist, umeclidinium bromide, and a long acting beta2 agonist, vilanterol trifenatate, is now available worldwide for COPD treatment. It provides COPD patients convenience, efficacy, and a very favorable adverse-effects profile. Additional once-daily combination inhalers are available or will soon be available for COPD patients worldwide. The use of once-daily combination inhalers will likely become the standard maintenance management approach in the treatment of COPD because they improve medication adherence.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalPatient Preference and Adherence
Volume9
DOIs
StatePublished - Feb 2 2015

Fingerprint

Nebulizers and Vaporizers
Chronic Obstructive Pulmonary Disease
medication
Medication Adherence
Muscarinic Antagonists
Disease
Chronic Disease
Therapeutics
Bromides
GSK573719
vilanterol
Adrenal Cortex Hormones
Maintenance
management

Keywords

  • Chronic obstructive pulmonary disease
  • Inhaled corticosteroid
  • Long-acting beta agonist
  • Long-acting muscarinic antagonist
  • Medication adherence

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

@article{3c4417342da1444489162a21be9d0cf2,
title = "Patient considerations in the treatment of COPD: Focus on the new combination inhaler umeclidinium/vilanterol",
abstract = "Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing. Once-daily dosing has been shown to be an important variable in medication adherence in chronic diseases, such as COPD. New inhalers that only require once-daily dosing are becoming more widely available. Combination once-daily inhalers that combine any two of the following three agents are now available: 1) a long-acting muscarinic antagonist; 2) a long acting beta2 agonist; and 3) an inhaled corticosteroid. A new once-daily inhaler with both a long-acting muscarinic antagonist, umeclidinium bromide, and a long acting beta2 agonist, vilanterol trifenatate, is now available worldwide for COPD treatment. It provides COPD patients convenience, efficacy, and a very favorable adverse-effects profile. Additional once-daily combination inhalers are available or will soon be available for COPD patients worldwide. The use of once-daily combination inhalers will likely become the standard maintenance management approach in the treatment of COPD because they improve medication adherence.",
keywords = "Chronic obstructive pulmonary disease, Inhaled corticosteroid, Long-acting beta agonist, Long-acting muscarinic antagonist, Medication adherence",
author = "Albertson, {Timothy E} and Harper, {Richart W} and Susan Murin and Sandrock, {Christian E}",
year = "2015",
month = "2",
day = "2",
doi = "10.2147/PPA.S71535",
language = "English (US)",
volume = "9",
pages = "235--242",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Patient considerations in the treatment of COPD

T2 - Focus on the new combination inhaler umeclidinium/vilanterol

AU - Albertson, Timothy E

AU - Harper, Richart W

AU - Murin, Susan

AU - Sandrock, Christian E

PY - 2015/2/2

Y1 - 2015/2/2

N2 - Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing. Once-daily dosing has been shown to be an important variable in medication adherence in chronic diseases, such as COPD. New inhalers that only require once-daily dosing are becoming more widely available. Combination once-daily inhalers that combine any two of the following three agents are now available: 1) a long-acting muscarinic antagonist; 2) a long acting beta2 agonist; and 3) an inhaled corticosteroid. A new once-daily inhaler with both a long-acting muscarinic antagonist, umeclidinium bromide, and a long acting beta2 agonist, vilanterol trifenatate, is now available worldwide for COPD treatment. It provides COPD patients convenience, efficacy, and a very favorable adverse-effects profile. Additional once-daily combination inhalers are available or will soon be available for COPD patients worldwide. The use of once-daily combination inhalers will likely become the standard maintenance management approach in the treatment of COPD because they improve medication adherence.

AB - Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing. Once-daily dosing has been shown to be an important variable in medication adherence in chronic diseases, such as COPD. New inhalers that only require once-daily dosing are becoming more widely available. Combination once-daily inhalers that combine any two of the following three agents are now available: 1) a long-acting muscarinic antagonist; 2) a long acting beta2 agonist; and 3) an inhaled corticosteroid. A new once-daily inhaler with both a long-acting muscarinic antagonist, umeclidinium bromide, and a long acting beta2 agonist, vilanterol trifenatate, is now available worldwide for COPD treatment. It provides COPD patients convenience, efficacy, and a very favorable adverse-effects profile. Additional once-daily combination inhalers are available or will soon be available for COPD patients worldwide. The use of once-daily combination inhalers will likely become the standard maintenance management approach in the treatment of COPD because they improve medication adherence.

KW - Chronic obstructive pulmonary disease

KW - Inhaled corticosteroid

KW - Long-acting beta agonist

KW - Long-acting muscarinic antagonist

KW - Medication adherence

UR - http://www.scopus.com/inward/record.url?scp=84922359203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922359203&partnerID=8YFLogxK

U2 - 10.2147/PPA.S71535

DO - 10.2147/PPA.S71535

M3 - Article

AN - SCOPUS:84922359203

VL - 9

SP - 235

EP - 242

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -